Takeda logo

Takeda Awards More Than $650,000 to Community Organizations through Health Equity Grant Program

Takeda Awards More Than $650,000 to Community Organizations through Health Equity Grant Program

CalendarMarch 29, 2023News Releases

- Funds awarded to community-based organizations that are working to advance health equity for medically underserved people with cancer

CAMBRIDGE, Massachusetts, March 29, 2023.– Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced more than $650,000 in grant funding was awarded to 18 organizations through the Improving Health Equity in Cancer: A Community Grant Program. The grants were provided to patient advocacy organizations that are helping to address the needs of medically underserved people with cancer through community-based initiatives.

“We are thrilled to be able to support advocacy organizations that are making a real impact for people with cancer in their local communities, as we know advancing health equity is not something that any one organization can do alone,” said Awny Farajallah, M.D., Head of Global Medical Affairs Oncology at Takeda. “By funding grassroots initiatives that help patients overcome the barriers to reaching their full health potential, we are able to advance equitable cancer care – something Takeda is deeply committed to.”

Eligibility for the awards required organizations to have programs that support one of three key areas - generating awareness of relevant and culturally appropriate health information, access to specialists and specialized treatments, and facilitating screening and diagnostic testing.

“By providing funding to programs that operate at a local level, we know our investment will facilitate action that has an immediate and direct impact on individual patient’s lives,” said Scott Campbell, Head of Oncology Patient Advocacy and Engagement at Takeda. “Countless local organizations are already combating health inequality in their communities, with tangible results that we are excited to contribute to.”

A full list of the awardees can be found below.

  • Advocates for Community Wellness, Inc


  • Cancer Services of Allen County, Inc.

  • Dia de la Mujer Latina Inc

  • Grinnell Regional Medical Center

  • LAHC-Leaders Advancing and Helping Communities

  • Legacy Training, Inc.

  • Little Red Door Cancer Agency

  • Make Well Known Foundation

  • National LGBT Cancer Network

  • Nebraska Cancer Coalition

  • Northeast Georgia Health System

  • Nueva Vida Inc

  • Patient Empowerment Network

  • The Chrysalis Initiative

  • Voice of The Experienced

  • Women's Cancer Resource Center

  • Worth the Wait

For more information about the Improving Health Equity in Cancer: A Community Grant Program, visit Improving Cancer Health Equity at the Local Level.

Takeda’s Commitment to Oncology

Our core R&D mission is to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. Whether it’s with our hematology therapies, our robust pipeline, or solid tumor medicines, we aim to stay both innovative and competitive to bring patients the treatments they need. For more information, visit www.takedaoncology.com.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries. For more information, visit https://www.takeda.com.

For more information, visit www.takedaoncology.com.

Media Contacts:

U.S. and International Media \ Sarah Gassmann \ [email protected] \ +1 610 836 2335

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings/ or at www.sec.govGo to www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

All trademarks are the property of their respective owners.

©2024 Takeda Pharmaceuticals U.S.A., Inc.

All rights reserved.   01/23